| pubmed-article:18035205 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18035205 | lifeskim:mentions | umls-concept:C0026769 | lld:lifeskim |
| pubmed-article:18035205 | lifeskim:mentions | umls-concept:C0008976 | lld:lifeskim |
| pubmed-article:18035205 | lifeskim:mentions | umls-concept:C0027796 | lld:lifeskim |
| pubmed-article:18035205 | lifeskim:mentions | umls-concept:C0006863 | lld:lifeskim |
| pubmed-article:18035205 | lifeskim:mentions | umls-concept:C0332281 | lld:lifeskim |
| pubmed-article:18035205 | lifeskim:mentions | umls-concept:C0231448 | lld:lifeskim |
| pubmed-article:18035205 | lifeskim:mentions | umls-concept:C0205318 | lld:lifeskim |
| pubmed-article:18035205 | pubmed:issue | 9 | lld:pubmed |
| pubmed-article:18035205 | pubmed:dateCreated | 2007-11-23 | lld:pubmed |
| pubmed-article:18035205 | pubmed:abstractText | Central neuropathic pain (CNP), pain initiated or caused by a primary lesion or dysfunction of the central nervous system, occurs in ~28% of patients with multiple sclerosis (MS). Delta(9)-Tetrahydrocannabinol/cannabidiol (THC/CBD), an endocannabinoid system modulator, has demonstrated efficacy for up to 4 weeks in randomized controlled trials in the treatment of CNP in patients with MS. | lld:pubmed |
| pubmed-article:18035205 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18035205 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18035205 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18035205 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18035205 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18035205 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18035205 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18035205 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18035205 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18035205 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18035205 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18035205 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:18035205 | pubmed:issn | 0149-2918 | lld:pubmed |
| pubmed-article:18035205 | pubmed:author | pubmed-author:NurmikkoTuro... | lld:pubmed |
| pubmed-article:18035205 | pubmed:author | pubmed-author:YoungCarolyn... | lld:pubmed |
| pubmed-article:18035205 | pubmed:author | pubmed-author:RogDavid JDJ | lld:pubmed |
| pubmed-article:18035205 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:18035205 | pubmed:volume | 29 | lld:pubmed |
| pubmed-article:18035205 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18035205 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18035205 | pubmed:pagination | 2068-79 | lld:pubmed |
| pubmed-article:18035205 | pubmed:meshHeading | pubmed-meshheading:18035205... | lld:pubmed |
| pubmed-article:18035205 | pubmed:meshHeading | pubmed-meshheading:18035205... | lld:pubmed |
| pubmed-article:18035205 | pubmed:meshHeading | pubmed-meshheading:18035205... | lld:pubmed |
| pubmed-article:18035205 | pubmed:meshHeading | pubmed-meshheading:18035205... | lld:pubmed |
| pubmed-article:18035205 | pubmed:meshHeading | pubmed-meshheading:18035205... | lld:pubmed |
| pubmed-article:18035205 | pubmed:meshHeading | pubmed-meshheading:18035205... | lld:pubmed |
| pubmed-article:18035205 | pubmed:meshHeading | pubmed-meshheading:18035205... | lld:pubmed |
| pubmed-article:18035205 | pubmed:meshHeading | pubmed-meshheading:18035205... | lld:pubmed |
| pubmed-article:18035205 | pubmed:meshHeading | pubmed-meshheading:18035205... | lld:pubmed |
| pubmed-article:18035205 | pubmed:meshHeading | pubmed-meshheading:18035205... | lld:pubmed |
| pubmed-article:18035205 | pubmed:meshHeading | pubmed-meshheading:18035205... | lld:pubmed |
| pubmed-article:18035205 | pubmed:meshHeading | pubmed-meshheading:18035205... | lld:pubmed |
| pubmed-article:18035205 | pubmed:meshHeading | pubmed-meshheading:18035205... | lld:pubmed |
| pubmed-article:18035205 | pubmed:meshHeading | pubmed-meshheading:18035205... | lld:pubmed |
| pubmed-article:18035205 | pubmed:meshHeading | pubmed-meshheading:18035205... | lld:pubmed |
| pubmed-article:18035205 | pubmed:meshHeading | pubmed-meshheading:18035205... | lld:pubmed |
| pubmed-article:18035205 | pubmed:meshHeading | pubmed-meshheading:18035205... | lld:pubmed |
| pubmed-article:18035205 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:18035205 | pubmed:articleTitle | Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial. | lld:pubmed |
| pubmed-article:18035205 | pubmed:affiliation | Walton Centre for Neurology and Neurosurgery, Liverpool, United Kingdom. djrdjr@doctors.org.uk | lld:pubmed |
| pubmed-article:18035205 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18035205 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:18035205 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18035205 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18035205 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18035205 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18035205 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18035205 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18035205 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18035205 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18035205 | lld:pubmed |
